VERTEX PHARMACEUTICALS INC / MA
VRTXAPI behind this page
VRTX Q2 2025 request
Playground key active
/api/financials?ticker=VRTX&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 2,964.7 | 2,645.6 | +12.1% |
Show Product Lines breakouts |
|||
| ALYFTREK | 156.8 | — | — |
| CASGEVY | 30.4 | — | — |
| JOURNAVX | 12 | — | — |
| Manufactured Product Other | 236.1 | 196.4 | +20.2% |
| Other revenues | 20.7 | — | — |
| Product | 2,944 | 2,645.6 | +11.3% |
| Product · Accumulated Translation Adjustment | -21.3 | 10.9 | -295.4% |
| Product · Europe | 910.9 | 806.8 | +12.9% |
| Product · Non Us | 1,116.5 | 1,031.3 | +8.3% |
| Product · Other | 205.6 | 224.5 | -8.4% |
| Product · US | 1,827.5 | 1,614.3 | +13.2% |
| TRIKAFTA/KAFTRIO | 2,551.1 | 2,449.2 | +4.2% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 2,964.7 | 2,645.6 | +12.1% |
| Cost of Revenue | 407.5 | 371.9 | +9.6% |
Show Product Lines breakouts |
|||
| Product · Pharmaceuticals | 140.5 | 123.5 | +13.8% |
| Royalty · Pharmaceuticals | 267 | 248.4 | +7.5% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 30.1 | 15.9 | +89.3% |
| Research And Development Expense Excluding Acquired In Process Cost | 978.4 | 966.6 | +1.2% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 15.1 | 11.6 | +30.2% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 2.2 | 4,449.1 | -100.0% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 2.2 | 4,449.1 | -100.0% |
| Selling, General & Administrative | 424.6 | 372.2 | +14.1% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 0.9 | 0.5 | +80.0% |
| Total Costs & Expenses | 1,813.6 | 6,160.3 | -70.6% |
| Operating Income | 1,151.1 | -3,514.7 | +132.8% |
| Investment Income Interest And Dividend | 122.4 | 156.5 | -21.8% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 122.4 | 156.5 | -21.8% |
| Interest Expense | -3.7 | -9.9 | +62.6% |
| Other Non-Operating Income (Expense) | 13.2 | -23.1 | +157.1% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Foreign Exchange Forward | -3.1 | -13.4 | +76.9% |
| Income Before Taxes | 1,283 | -3,391.2 | +137.8% |
| Income Tax Expense (Benefit) | 250.1 | 202.4 | +23.6% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 250.1 | 202.4 | +23.6% |
| Net Income | 1,032.9 | -3,593.6 | +128.7% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 1,032.9 | -3,593.6 | +128.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,032.9 | -3,593.6 | +128.7% |
| EPS (Basic) | 4.02 | -13.92 | +128.9% |
| EPS (Diluted) | 3.99 | -13.92 | +128.7% |
| Wtd Avg Shares (Basic) | 256.7 | 258.1 | -0.5% |
| Wtd Avg Shares (Diluted) | 258.9 | 258.1 | +0.3% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 160 | 175.9 | -9.0% |
| Comprehensive Income | 863.7 | -3,588.4 | +124.1% |
| Other Comprehensive Income | -169.2 | 5.2 | -3353.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -169.2 | 5.2 | -3353.8% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,972.2 | 4,580.1 | +8.6% |
| Marketable Securities (Current) | 1,410.6 | 1,215.4 | +16.1% |
| Accounts Receivable | 1,893.5 | 1,656.1 | +14.3% |
| Inventory | 1,499.3 | 914.6 | +63.9% |
| Prepaid Expenses & Other Current Assets | 652.3 | 575.4 | +13.4% |
| Total Current Assets | 10,427.9 | 8,941.6 | +16.6% |
| Non-Current Assets | |||
| Goodwill | 1,088 | 1,088 | 0.0% |
| Deferred Tax Assets | 2,711.7 | 2,185.6 | +24.1% |
| Operating Lease Right-of-Use Assets | 1,313.8 | 569.8 | +130.6% |
| Marketable Securities (Non-Current) | 5,645.9 | 4,393.1 | +28.5% |
| Other Non-Current Assets | 1,078.8 | 915.6 | +17.8% |
| Total Assets | 24,036.7 | 20,132.1 | +19.4% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Employment Contracts | 4.9 | — | — |
| Marketing Related Intangible Assets | 206 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,335.1 | 1,200.9 | +11.2% |
| Intangible Assets Net Excluding Goodwill | 435.5 | — | — |
| Current Liabilities | |||
| Accounts Payable | 442.3 | 327.9 | +34.9% |
| Accrued Liabilities | 3,270.7 | 2,940 | +11.2% |
| Other Liabilities Current | 425.4 | 279.3 | +52.3% |
| Total Current Liabilities | 4,138.4 | 3,547.2 | +16.7% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 1,527.4 | 586.8 | +160.3% |
| Other Non-Current Liabilities | 1,195.5 | 876.8 | +36.3% |
| Total Liabilities | 6,861.3 | 5,357.4 | +28.1% |
| Stockholders' Equity | |||
| Common Stock | 2.6 | 2.6 | 0.0% |
| Additional Paid In Capital Common Stock | 5,987.9 | 7,101.2 | -15.7% |
| Accumulated Other Comprehensive Income | -101.1 | 22.5 | -549.3% |
| Retained Earnings | 11,286 | 7,648.4 | +47.6% |
| Total Stockholders' Equity | 17,175.4 | 14,774.7 | +16.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -171.2 | 31.3 | -647.0% |
| Accumulated Net Unrealized Investment Gain Loss | 31 | -15.5 | +300.0% |
| Accumulated Other Comprehensive Income | -101.1 | 22.5 | -549.3% |
| Accumulated Translation Adjustment | 39.1 | 6.7 | +483.6% |
| Additional Paid In Capital | 5,987.9 | 7,101.2 | -15.7% |
| Common Stock | 2.6 | 2.6 | 0.0% |
| Retained Earnings | 11,286 | 7,648.4 | +47.6% |
| Total Liabilities & Equity | 24,036.7 | 20,132.1 | +19.4% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 333.4 | 346.1 | -3.7% |
| Depreciation & Amortization | 100.1 | 107.5 | -6.9% |
| Increase Decrease In Other Deferred Liability | -305.4 | -277.1 | -10.2% |
| Equity Securities Fv Ni Unrealized Gain Loss | 9.6 | 39.7 | -75.8% |
| Other Non-Cash Items | 97 | -57.1 | +269.9% |
| Change in Accounts Receivable | -188 | -116.5 | -61.4% |
| Change in Inventory | -315.7 | -187.3 | -68.6% |
| Change in Prepaid & Other Assets | -104.5 | -56.7 | -84.3% |
| Change in Accounts Payable | 33.8 | -25 | +235.2% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 214.7 | 362.4 | -40.8% |
| Increase Decrease In Other Operating Liabilities | -41.2 | -89 | +53.7% |
| Net Cash from Operations | 1,892 | -2,447 | +177.3% |
| Investing Activities | |||
| Purchases of Investments | -3,820.6 | -3,895.1 | +1.9% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 3,476.3 | 1,893.1 | +83.6% |
| Capital Expenditures | -186.4 | -137.4 | -35.7% |
| Other Investing Activities | -9.6 | -15 | +36.0% |
| Net Cash from Investing | -540.3 | -2,600.1 | +79.2% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 65.8 | 71.9 | -8.5% |
| Share Repurchases | -817.9 | -451.5 | -81.2% |
| Tax Withholding for Share Compensation | -276.4 | -314 | +12.0% |
| Finance Lease Principal Payments | -2.6 | -26.9 | +90.3% |
| Proceeds From Payments For Other Financing Activities | 1.5 | 4.4 | -65.9% |
| Net Cash from Financing | -1,029.6 | -716.1 | -43.8% |
| Supplemental | |||
| Income Taxes Paid | 697.7 | 531.8 | +31.2% |
| Interest Paid | 6.2 | 19.7 | -68.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 87.7 | -18.1 | +584.5% |
| Net Change in Cash | 409.8 | -5,781.3 | +107.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,982 | 4,591 | +8.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.